PRKAB1 and fatty liver disease: As noted above, AMPK most likely improves hepatic steatosis and hypertriglyceridemia by inhibiting lipogenesis through increased phosphorylation (inactivation) of ACC and secondarily by promoting hepatic fatty acid oxidation via suppression of malonyl CoA levels.